Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9963147 | 0.90 | PIK3CD (0.30) | — | |
| SCHEMBL9963278 | 0.89 | CYP2D6 (0.38) | CYP2D6IDO1 | |
| SCHEMBL12758823 | 0.76 | OPRM1 (0.34) | CYP2D6SMN1; SMN2 | |
| SCHEMBL16559762 | 0.74 | CYP2D6 (0.34) | CYP2D6SMN1; SMN2 | |
| SCHEMBL12835659 | 0.73 | CHRM2 (0.41) | — | |
| SCHEMBL12832197 | 0.73 | CYP2D6 (0.33) | CYP2D6SMN1; SMN2 | |
| SCHEMBL20420099 | 0.72 | ACACB (0.33) | CYP2D6 | |
| SCHEMBL16559744 | 0.71 | OTUD7B (0.36) | CYP2D6SMN1; SMN2 | |
| SCHEMBL27050945 | 0.71 | CYP2D6 (0.33) | CYP2D6SMN1; SMN2 | |
| SCHEMBL16750973 | 0.71 | USP2 (0.32) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | CYP2D6 1147/4885IDO1 1421/4885SMN1; SMN2 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.